Video

In the 'Midst of a Real Shakeup': Perspective on Next Few Years of Mantle Cell Lymphoma Treatments

Author(s):

“I think we’re in a midst of a real shakeup in our treatment paradigms for patients with mantle cell lymphoma, or at least we will be in the next few years,” said Dr. Ian Flinn in an interview with CURE®.

In a recent interview with CURE®, Dr. Ian Flinn, director of lymphoma research at Sarah Cannon Research Institute, discussed what treatment for mantle cell lymphoma may look like over the next several years.

“I think we’re in a midst of a real shakeup in our treatment paradigms for patients with mantle cell lymphoma, or at least we will be in the next few years,” Flinn said.

Transcription:

I think we’re in a midst of a real shakeup in our treatment paradigms for patients with mantle cell lymphoma, or at least we will be in the next few years.

One of the most common therapies for patients with mantle cell lymphoma right now is they get induction chemotherapy, sometimes very aggressive chemotherapy, and then follow it with an autologous peripheral blood stem cell transplant. Basically, a way of giving people very high doses of chemotherapy to overcome resistance to lower doses of chemotherapy and keep people in remission for a longer period of time.

I think the hope is that we’ll be able to get rid of that, right, I mean that is a very aggressive therapy, very difficult therapy that many patients, certainly patients above 70 or so, it’s not probably available to them because of the side effects, and sometimes younger patients want to avoid these as well, so some of these combination therapies that I’m talking about. Such as the combinations of BTK inhibitor and venetoclax (Venclexta) or you know therapies like that, are, I think ultimately going to make their way earlier in the course of therapy and hopefully free us from some of these chemotherapy backbones.

Related Videos
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image od grey haired Doctor.
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Image of man with grey hair.
Image of man with black hair.
Image of doctor with grey hair.
Image of doctor with black hair.